Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Public ClinicalTrials.gov record NCT03402659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Study identification
- NCT ID
- NCT03402659
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2017 (Actual)
- Primary completion
- Jun 30, 2019 (Actual)
- Completion
- Jul 31, 2019 (Actual)
- Last update posted
- Oct 27, 2021
2017 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance for Research | Long Beach | California | 90807 | — |
| Pacific Research Network | San Diego | California | 92103 | — |
| CITrials | Santa Ana | California | 92705 | — |
| Southern California Research, LLC | Simi Valley | California | 93065 | — |
| Viking Clinical Research | Temecula | California | 92591 | — |
| Miami Dade Medical Research Institute | Miami | Florida | 33176 | — |
| Sensible Healthcare, LLC | Ocoee | Florida | 34761 | — |
| Anchor Neuroscience | Pensacola | Florida | 32502 | — |
| Progressive Medical Research | Port Orange | Florida | 32127 | — |
| Suncoast Neuroscience Associates, Inc. | St. Petersburg | Florida | 33713 | — |
| Florida Premier Research Institute | Winter Park | Florida | 32789 | — |
| Northwest Clinical Trials | Boise | Idaho | 83704 | — |
| MassGeneral Institute for Neurodegenerative Disease | Charlestown | Massachusetts | 02129 | — |
| Manhattan Behavioral Medicine | New York | New York | 10036 | — |
| Alzheimer's Memory Center and Research Institute | Charlotte | North Carolina | 28270 | — |
| Northwest Clinical Research Center | Seattle | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03402659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03402659 live on ClinicalTrials.gov.